Company: Raytelligence AB

Transaction: Rights issue

Issue volume: 26.3 MSEK

Date: November 2020

Raytelligence offers products and services for non-contact monitoring vital signs of humans, that is respiration, heartbeat and motion patterns based on the company’s own 60 GHz radar technology.

Raytelligence’s shares are listed on NGM Nordic SME.

Augment acted as financial advisor to the company in the rights issue.